FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Guidance on New Chemical Entity Exclusivity on Fixed-Combo Drugs

[ Price : $8.95]

Federal Register Notice: FDA releases a new guidance: New Chemical Entity Exclusivity Determinations for Certain Fixed-Combination...

Canadian Web Site Selling Unapproved HIV Tests

[ Price : $8.95]

CBER says a Canadian Web site is illegally promoting unapproved at-home HIV tests for sale in the U.S.

FDA Says Generic BE Not Impacted by Software Concerns

[ Price : $8.95]

FDA says that generic bioequivalence determinations are not impacted by recent concerns raised by a scientific article that questi...

FDA Approves Expanded Use of Lymphoseek

[ Price : $8.95]

FDA approves a Navidea Biopharmaceuticals supplemental NDA for the expanded use of Lymphoseek (technetium Tc 99m tilmanocept) inje...

FDA Accepts Eisai NDA for Treating Thyroid Cancer

[ Price : $8.95]

FDA accepts for priority review an Eisai NDA for its in-house developed anticancer agent lenvatinib mesylate as a treatment for pr...

Comments Sought on Condom Labeling

[ Price : $8.95]

Federal Register Notice: FDA seeks comments on an information collection on the labeling of natural rubber latex condoms.

Guidance on Device Recalls vs. Enhancements

[ Price : $8.95]

Federal Register Notice: FDA releases a guidance on distinguishing device recalls from medical device enhancements.

FDA Approves 2 NDAs for Idiopathic Pulmonary Fibrosis

[ Price : $8.95]

FDA approves two NDAs ahead of their user fee goal dates for treating idiopathic pulmonary fibrosis.

Hospira Recalls Several LifeCare Products Due to Leakage

[ Price : $8.95]

Hospira recalls certain lots of several products in its LifeCare line of flexible intravenous solutions due to the potential for l...

ADR Network Wants Levaquin Psychiatric Labeling Info

[ Price : $8.95]

The Southern Network on Adverse Reactions asks FDA to require addition of specific psychiatric adverse events to Levaquin labeling...